Randomized trial · people

Abaloparatide raised hip BMD around a virtual hip stem in ACTIVE

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In postmenopausal women with osteoporosis, abaloparatide raised bone density in thigh-bone regions around a simulated hip stem, though whether that improves hip replacement outcomes was not tested.

Kind
Randomized trial
Studied in
People
Number studied
500
Published
2024
Journal
J Bone Joint Surg Am

What they tested

The team wanted to know whether abaloparatide improves bone density in the upper thigh-bone regions that would surround the stem of a hip replacement.

How the study was done

A post hoc analysis (a look back at data collected for another purpose) of the randomized, placebo-controlled phase 3 ACTIVE trial, using hip DXA scans (a type of x-ray bone scan) from 500 randomly picked postmenopausal women with osteoporosis: 250 on abaloparatide and 250 on placebo, scanned at 0, 6 and 18 months. The scans were turned into 3D models, a tapered hip stem was placed virtually, and bone was measured in the Gruen zones (standard regions around a hip stem) 1, 2, 6 and 7.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Compared with placebo, women on abaloparatide had larger gains in integral volumetric BMD (overall bone density through the whole bone volume) in every zone at both 6 and 18 months. By 18 months, cortical thickness, cortical volumetric BMD and cortical surface BMD (measures of the dense outer bone layer) had also risen more in every zone, and cortical surface BMD was already higher in zones 1, 6 and 7 at 6 months. Trabecular volumetric BMD (density of the spongy inner bone) rose more in zones 1 and 7 at both time points.

What it doesn’t show

This was a post hoc analysis, and the hip stem was only placed virtually on scans, so it measured bone density rather than any real implant. It did not test surgical outcomes such as fractures around an implant or implant stability, and it included only postmenopausal women with osteoporosis.

The paper

Sheth et al. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis. J Bone Joint Surg Am. 2024.

The compound

More studies on Abaloparatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking abaloparatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo